Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463155 | 1.00 | KMT2A (0.41) | KMT2AMEN1EGFRIDH1SMN1; SMN2 | |
| SCHEMBL14429480 | 0.87 | KMT2A (0.36) | KMT2AMEN1EGFRIDH1MAPK1 | |
| SCHEMBL10249316 | 0.81 | LMNA (0.42) | KMT2AMEN1IDH1MAPK1LMNA | |
| SCHEMBL14429479 | 0.81 | EGFR (0.39) | KMT2AMEN1EGFRIDH1MAPK1 | |
| SCHEMBL5017235 | 0.81 | LMNA (0.42) | KMT2AMEN1IDH1MAPK1LMNA | |
| SCHEMBL10252636 | 0.81 | LMNA (0.42) | KMT2AMEN1IDH1MAPK1LMNA | |
| SCHEMBL14429441 | 0.81 | EGFR (0.39) | KMT2AMEN1EGFRIDH1MAPK1 | |
| SCHEMBL14429487 | 0.81 | EGFR (0.39) | KMT2AMEN1EGFRIDH1MAPK1 | |
| SCHEMBL5016477 | 0.79 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL1690433 | 0.78 | HSD11B1 (0.48) | KMT2AMEN1IDH1HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
| US-7807700-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | KMT2A 3049/4885MEN1 806/4885EGFR 4777/4885 |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | KMT2A 3049/4885MEN1 806/4885EGFR 4777/4885 |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | KMT2A 3245/4885MEN1 877/4885EGFR 4868/4885 |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | KMT2A 3049/4885MEN1 806/4885EGFR 4777/4885 |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | HSD11B1, HSD3B1, HSD17B1 | KMT2A 2612/4885MEN1 899/4885EGFR 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.